• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. disposed of 18,156,867 units of Class B Common Stock and converted options into 18,156,867 shares (SEC Form 4)

    5/26/26 4:05:15 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care
    Get the next $MDLN alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Hellman & Friedman Capital Partners X (Parallel), L.P.

    (Last)(First)(Middle)
    C/O HELLMAN & FRIEDMAN LLC
    415 MISSION STREET, SUITE 5700

    (Street)
    SAN FRANCISCO CALIFORNIA 94105

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Medline Inc. [ MDLN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    05/21/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    XForm filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Class A Common Stock05/21/2026C(1)(2)18,156,867A(1)18,176,177IBy Mend Investment Holdings I, L.P.(3)(4)
    Class B Common Stock05/21/2026J(2)(5)18,156,867D(5)82,453,349IBy Mend Investment Holdings I, L.P.(3)(4)
    Class A Common Stock74,496,172IBy Hellman & Friedman Capital Partners X (Parallel), L.P.(3)(4)
    Class A Common Stock7,781,788IBy HFCP X (Parallel - A), L.P.(3)(4)
    Class A Common Stock4,176,227IBy Mend Partners II, L.P.(3)(4)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Common Units(1)05/21/2026C(1)(2)18,156,867 (1) (1)Class A Common Stock18,156,867(1)82,453,349IBy Mend Investment Holdings I, L.P.(2)(3)
    1. Name and Address of Reporting Person*
    Hellman & Friedman Capital Partners X (Parallel), L.P.

    (Last)(First)(Middle)
    C/O HELLMAN & FRIEDMAN LLC
    415 MISSION STREET, SUITE 5700

    (Street)
    SAN FRANCISCO CALIFORNIA 94105

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    HFCP X (Parallel-A), L.P.

    (Last)(First)(Middle)
    C/O HELLMAN & FRIEDMAN LLC
    415 MISSION STREET, SUITE 5700

    (Street)
    SAN FRANCISCO CALIFORNIA 94105

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    Mend Partners II, L.P.

    (Last)(First)(Middle)
    C/O HELLMAN & FRIEDMAN LLC
    415 MISSION STREET, SUITE 5700

    (Street)
    SAN FRANCISCO CALIFORNIA 94105

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    Mend Investment Holdings I, L.P.

    (Last)(First)(Middle)
    C/O HELLMAN & FRIEDMAN LLC
    415 MISSION STREET, SUITE 5700

    (Street)
    SAN FRANCISCO CALIFORNIA 94105

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    Hellman & Friedman Investors X, L.P.

    (Last)(First)(Middle)
    C/O HELLMAN & FRIEDMAN LLC
    415 MISSION STREET, SUITE 5700

    (Street)
    SAN FRANCISCO CALIFORNIA 94105

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    Mend Partners GP, LLC

    (Last)(First)(Middle)
    C/O HELLMAN & FRIEDMAN LLC
    415 MISSION STREET, SUITE 5700

    (Street)
    SAN FRANCISCO CALIFORNIA 94105

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    Mend Investment Holdings GP, LLC

    (Last)(First)(Middle)
    C/O HELLMAN & FRIEDMAN LLC
    415 MISSION STREET, SUITE 5700

    (Street)
    SAN FRANCISCO CALIFORNIA 94105

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    Hellman & Friedman Capital Partners X, L.P.

    (Last)(First)(Middle)
    C/O HELLMAN & FRIEDMAN LLC
    415 MISSION STREET, SUITE 5700

    (Street)
    SAN FRANCISCO CALIFORNIA 94105

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    H&F Corporate Investors X, Ltd.

    (Last)(First)(Middle)
    C/O HELLMAN & FRIEDMAN LLC
    415 MISSION STREET, SUITE 5700

    (Street)
    SAN FRANCISCO CALIFORNIA 94105

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    Explanation of Responses:
    1. Pursuant to the terms of an exchange agreement, dated as of December 16, 2025, holders have the right to exchange the common units of Medline Holdings, LP ("Common Units") for shares of Class A common stock ("Class A Common Stock") of Medline Inc. (the "Issuer"), on a one-for-one basis, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. These exchange rights do not expire
    2. On May 21, 2026, Mend Investment Holdings I, L.P. exchanged 18,156,867 Common Units for an equal number of shares of Class A Common Stock and the Issuer automatically cancelled an equivalent number of shares of the Class B common stock ("Class B Common Stock") of the Issuer held by Mend Investment Holdings I, L.P.
    3. Hellman & Friedman Investors X, L.P. ("Investors X GP") is the general partner of Hellman & Friedman Capital Partners X (Parallel), L.P. and HFCP X (Parallel - A), L.P. Mend Partners GP, LLC ("Mend GP") is the general partner of Mend Partners II, L.P. Investors X GP is the managing member of Mend GP. Mend Investment Holdings GP, LLC ("Mend Investment GP") is the general partner of Mend Investment Holdings I, L.P. Hellman & Friedman Capital Partners X, L.P. ("HFCP X") is the managing member of Mend Investment GP. Investors X GP is the general partner of HFCP X. H&F Corporate Investors X, Ltd. ("Investors X Ltd.") is the general partner of Investors X GP.
    4. (Continued from footnote 3) A three-member board of directors of Investors X Ltd. has voting and investment discretion over the securities held by Hellman & Friedman Capital Partners X (Parallel), L.P., HFCP X (Parallel - A), Mend Partners II, L.P., and Mend Investment Holdings I, L.P. Each of the members of the board of directors of Investors X Ltd. disclaims beneficial ownership of such shares.
    5. Shares of the Class B Common Stock have no economic value and have one vote per share. One share of Class B Common Stock is issued for each Common Unit held. Upon an exchange of Common Units for shares of the Class A common stock, an equivalent number of shares of Class B Common Stock held by such holder will be automatically cancelled.
    Remarks:
    The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act. This filing shall not be deemed an admission that for purposes of Section 16 of the Exchange Act, or otherwise, that the Reporting Persons are subject to Section 16 of the Exchange Act or that the Reporting Persons are the beneficial owners of any equity securities in excess of their respective pecuniary interests, and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.
    By: /s/ Jacob Best; Jacob Best, Vice President of H&F Corporate Investors X, Ltd., the general partner of Hellman & Friedman Investors X, L.P., the general partner of Hellman & Friedman Capital Partners X (Parallel), L.P.05/26/2026
    By: /s/ Jacob Best; Jacob Best, Vice President of H&F Corporate Investors X, Ltd., the general partner of Hellman & Friedman Investors X, L.P., the general partner of HFCP X (Parallel - A), L.P.05/26/2026
    By: /s/ Jacob Best; Jacob Best, Vice President of H&F Corporate Investors X, Ltd., the general partner of Hellman & Friedman Investors X, L.P., the managing member of Mend Partners GP, LLC, the general partner of Mend Partners II, L.P.05/26/2026
    By: /s/ Jacob Best; VP of H&F Corporate Investors X, Ltd., the GP of Hellman & Friedman Investors X, L.P., the GP of Hellman & Friedman Capital Partners X, L.P., the MM of Mend Investment Holdings GP, LLC, the GP of Mend Investment Holdings I, L.P.05/26/2026
    By: /s/ Jacob Best; Jacob Best, Vice President of H&F Corporate Investors X, Ltd., the general partner of Hellman & Friedman Investors X, L.P.05/26/2026
    By: /s/ Jacob Best; Jacob Best, Vice President of H&F Corporate Investors X, Ltd., the general partner of Hellman & Friedman Investors X, L.P., the managing member of Mend Partners GP, LLC05/26/2026
    By: /s/ Jacob Best; Jacob Best, Vice President of H&F Corporate Investors X, Ltd., the general partner of Hellman & Friedman Investors X, L.P., the G.P. of Hellman & Friedman X Capital Partners, L.P., the managing member of Mend Investment Holding GP LLC05/26/2026
    By: /s/ Jacob Best; Jacob Best, Vice President of H&F Corporate Investors X, Ltd., the general partner of Hellman & Friedman Investors X, L.P., the general partner of Hellman & Friedman Capital Partners X, L.P.05/26/2026
    By: /s/ Jacob Best; Jacob Best, Vice President of H&F Corporate Investors X, Ltd.05/26/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $MDLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDLN

    DatePrice TargetRatingAnalyst
    3/11/2026$60.00Buy
    Citigroup
    2/5/2026$55.00Buy
    Tigress Financial
    1/21/2026$50.00 → $55.00Buy
    BTIG Research
    1/12/2026$48.00Buy
    Citigroup
    1/12/2026$38.00Neutral
    BNP Paribas Exane
    1/12/2026$50.00Overweight
    Analyst
    1/12/2026$50.00Overweight
    Piper Sandler
    1/12/2026$48.00Overweight
    Morgan Stanley
    More analyst ratings

    $MDLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medline's Prime Vendor model expands outside the United States

    Agreement with Mohawk Medbuy in Canada marks first-of-its-kind Prime Vendor relationship outside the U.S.NORTHFIELD, Ill., May 29, 2026 /PRNewswire/ -- Medline (NASDAQ:MDLN) announced that Medline Canada has signed its first Prime Vendor agreement in the country and is the first Medline Prime Vendor relationship outside the United States. The agreement is with Mohawk Medbuy (MMC), one of Canada's largest healthcare procurement organizations, to support warehouse and supply chain logistics for its hospitals in Southwestern Ontario and builds from best practices from similar agreements with hundreds of healthcare providers in the U.S.

    5/29/26 10:25:00 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Medline Inc. announces closing of upsized secondary offering of Class A common stock

    NORTHFIELD, Ill., May 28, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (NASDAQ:MDLN) ("Medline") announced today that it has closed its upsized secondary offering of 72,554,594 shares of Medline Inc.'s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the "Selling Stockholders") at a price to the public of $37.00 per share. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 10,883,189 shares of Medline's Class A common stock. Medline did not sell any shares of Class A common stock in the offering and did not recei

    5/28/26 4:30:00 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Medline announces participation in upcoming investor conferences

    NORTHFIELD, Ill., May 27, 2026 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline") (NASDAQ:MDLN) today announced that members of the executive leadership team will be participating in the following investor conferences. Mike Drazin, chief financial officer, and Amanda Laabs, chief product officer, are scheduled to present at the William Blair 46th Annual Growth Stock Conference in Chicago, IL, on Wednesday, June 3, 2026, at 3:40pm ET.Jim Boyle, chief executive officer, and Mike Drazin, chief financial officer, are scheduled to present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL, on Tuesday, June 9, 2026, at 10:40am ET. Webcasts of the presentations will be a

    5/27/26 7:30:00 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup resumed coverage on Medline with a new price target

    Citigroup resumed coverage of Medline with a rating of Buy and set a new price target of $60.00

    3/11/26 8:38:58 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Tigress Financial initiated coverage on Medline with a new price target

    Tigress Financial initiated coverage of Medline with a rating of Buy and set a new price target of $55.00

    2/5/26 10:03:24 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    BTIG Research reiterated coverage on Medline with a new price target

    BTIG Research reiterated coverage of Medline with a rating of Buy and set a new price target of $55.00 from $50.00 previously

    1/21/26 1:17:48 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gic Private Ltd sold $289,480,090 worth of shares (10,204,351 units at $28.37) and bought $364,999,974 worth of shares (12,586,206 units at $29.00) (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    12/22/25 5:26:57 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Director Mills Andrew J. was granted 30,655 units of Class B Common Stock and bought $74,999,974 worth of shares (2,586,206 units at $29.00) (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    12/22/25 4:30:06 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Director Mills Charles N. was granted 64,005 units of Class B Common Stock and bought $74,799,990 worth of shares (2,579,310 units at $29.00) (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    12/22/25 4:30:04 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    SEC Filings

    View All

    Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement

    8-K - Medline Inc. (0002046386) (Filer)

    6/2/26 8:06:32 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    SEC Form 424B4 filed by Medline Inc.

    424B4 - Medline Inc. (0002046386) (Filer)

    5/26/26 4:05:33 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Medline Inc.

    EFFECT - Medline Inc. (0002046386) (Filer)

    5/22/26 12:15:23 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    6/1/26 6:16:21 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    6/1/26 6:05:43 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    6/1/26 4:15:05 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    Financials

    Live finance-specific insights

    View All

    MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

    EscharEx® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed at $24-26 million Conference Call Today, May 27, 2026, at 8:30 a.m. Eastern Time YAVNE, Israel, May 27, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update. "During the first quarter, we continued to advance both our strategic and operational priorities," said Ofer Gonen, Chief Execut

    5/27/26 7:00:00 AM ET
    $MDLN
    $MDWD
    Medical/Dental Instruments
    Health Care
    Medicinal Chemicals and Botanical Products

    Medline Reports First Quarter 2026 Results

    Net sales of $7.4 billion, an increase of 10.7%Net income of $239 million, a decrease of 25.8%Adjusted EBITDA1 of $776 million, a decrease of 10.6%Raising full year 2026 Organic Sales2 guidance range to 8.5% to 9.5% NORTHFIELD, Ill., May 06, 2026 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline" or the "Company") (NASDAQ:MDLN), the largest provider of medical-surgical ("med-surg") products and supply chain solutions serving all points of care3, today reported its operating results for the three months ended March 28, 2026. "We started 2026 with strong momentum—growing with our existing customers, executing implementations at scale and winning new customers," said Jim Boyle, chief executive off

    5/6/26 7:30:00 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Medline to report first quarter 2026 results on May 6, 2026

    NORTHFIELD, Ill., April 08, 2026 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline") (NASDAQ:MDLN) today announced that it plans to report first quarter 2026 financial results on Wednesday, May 6, 2026. A press release and supplemental materials will be issued before the market opens. The company will host a webcast and conference call at 9:30am ET/ 8:30am CT to discuss the financial results. Information about Medline's financial results, including a link to the live webcast, will be available on the Events page of Medline's Investor Relations website at ir.medline.com. A replay of the webcast will be available following the event through the same website. About MedlineMedline is the largest pr

    4/8/26 9:00:00 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care